✦ LIBER ✦

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial

✍ Scribed by Saridaki, Z; Androulakis, N; Vardakis, N; Vamvakas, L; Kabouraki, E; Kalbakis, K; Hatzidaki, D; Voutsina, A; Mavroudis, D; Georgoulias, V; Souglakos, J

Book ID: 120058631
Publisher: Nature Publishing Group
Year: 2012
Tongue: English
Weight: 242 KB
Volume: 107
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.2012.509

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Irinotecan (CPT-11) plus oxaliplatin (LO

Irinotecan (CPT-11) plus oxaliplatin (LOHP) plus infusional 5-fluorouracil (5-FU) and leukovorin (LV) as first line treatment for metastatic colorectal cancer (MCC): A phase II trial

✍ Souglakos, J.; Kakolyris, S.; Athanasiadis, A.; Kouroussis, Ch.; Mavroudis, D.; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 197 KB

A multicenter phase II study of irinotec

A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer

✍ JuanJosé Reina; Jorge Aparicio; Javier Salvador; JoséMaríaPuerto Pica; Antonio R 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 192 KB

6096 POSTER FOLFOXIRI (Irinotecan, Oxali

6096 POSTER FOLFOXIRI (Irinotecan, Oxaliplatin, and Infusional 5FU/LV) in Combination With Panitumumab (P) in the First-line Treatment of Metastatic Colorectal Cancer (mCRC) Patients (pts) Selected for KRAS, BRAF, NRas and HRas Mutational Status – a Phase II Study by the G.O.N.O. Group

✍ Fornaro, L.; Loupakis, F.; Lonardi, S.; Masi, G.; Salvatore, L.; Cremolini, C.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 49 KB